{"id":474060,"date":"2020-03-16T11:22:02","date_gmt":"2020-03-16T11:22:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=474060"},"modified":"2020-03-16T11:22:02","modified_gmt":"2020-03-16T11:22:02","slug":"wet-age-related-macular-degeneration-pipeline-therapies-shifting-wet-amd-market-scenario","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/wet-age-related-macular-degeneration-pipeline-therapies-shifting-wet-amd-market-scenario_474060.html","title":{"rendered":"Wet Age Related Macular Degeneration Pipeline therapies shifting Wet AMD market scenario"},"content":{"rendered":"
\"Wet<\/a><\/p>\n
\n
DelveInsight Pipeline reports <\/div>\n<\/div>\n<\/div>\n
Wet Age-related Macular Degeneration Pipeline (Wet AMD Pipeline) analysis by DelveInsight offers a detailed description of Wet Age-related macular degeneration pipeline products, their expected launch, exhaustive competitive benchmarking, and key pharma companies working in the same field. <\/div>\n

Wet Age-related Macular Degeneration <\/strong>is a condition, which results in deterioration of the macula – a tiny spot on the retina – responsible for vision. generally, the macular degeneration starts as a dry type and eventually becomes Wet resulting in a leak in fluid and blood vessels. <\/p>\n

According to studies, approximately, 200,000 new cases of Wet AMD are diagnosed with each year in the U.S and Wet AMD result in the cause of 90% of AMD-related severe vision loss.<\/strong><\/p>\n

DelveInsight’s Wet Age-related macular degeneration pipeline report <\/strong>covers an overview of the disease, comprehensive insights into the preclinical landscape, listing their mechanism of action, administration routes, active pharmaceutical entity, and their launch dates. <\/p>\n

The report also covers some of the important aspects of the Wet AMD market including the present marketed drugs for the condition, and  NDA approvals (if any), and product development activities comprising the technology, Wet Age-Related Macular Degeneration (Wet AMD) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details. <\/p>\n

\"\"<\/p>\n

Key highlights of the report <\/strong><\/p>\n

Companies working in the Wet Age-related macular degeneration market <\/p>\n

Collaboration of the companies <\/p>\n

Licensing In\/out opportunities <\/p>\n

Therapies segmented into Phases of development <\/p>\n

Targeted therapeutics development with respective active and inactive (dormant or discontinued) projects…<\/p>\n

Request for Sample pages<\/a><\/p>\n

The report is built using data and information traced from the researcher’s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university web sites and industry-specific third-party sources, etc.<\/p>\n

 Wet Age-Related Macular Degeneration (Wet AMD) Clinical Assessment of products <\/p>\n

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.<\/p>\n

Major pharma companies advancing the Wet Age-related macular degeneration market are Allergan, Bioeq, Alkahest, GrayBug Vision, Eyepoint pharma, Innovent Biologics, Kodiak Sciences, Opthea PanOptica, and Adverum Biotechnologies are steering the Wet AMD market forward. <\/strong><\/p>\n

The emerging therapies such as Abicipar pegol by Allergan, FYB201 by Bioeq, KSI-301 by Kodiak Sciences and several others are going to enter into the Wet AMD therapy market soon.<\/strong><\/p>\n

 <\/p>\n

Table of Contents<\/a><\/p>\n

1. Report Introduction<\/p>\n

2. Wet Age-Related Macular Degeneration (Wet AMD)<\/p>\n

3. Wet Age-Related Macular Degeneration (Wet AMD) Current Treatment Patterns<\/p>\n

3.1. Wet Age-Related Macular Degeneration (Wet AMD) Treatment Guidelines<\/p>\n

4. Wet Age-Related Macular Degeneration (Wet AMD) – DelveInsight’s Analytical Perspective<\/p>\n

5. Therapeutic Assessment<\/p>\n

6. Wet Age-Related Macular Degeneration (Wet AMD) Late Stage Products (Phase-III)<\/p>\n

7. Wet Age-Related Macular Degeneration (Wet AMD) Mid Stage Products (Phase-II)<\/p>\n

8. Early Stage Products (Phase-I)<\/p>\n

9. Pre-clinical Products and Discovery Stage Products<\/p>\n

10. Inactive Products<\/p>\n

11. Dormant Products<\/p>\n

12. Wet Age-Related Macular Degeneration (Wet AMD) Discontinued Products<\/p>\n

13. Wet Age-Related Macular Degeneration (Wet AMD) Product Profiles<\/p>\n

14. Wet Age-Related Macular Degeneration (Wet AMD) Key Companies<\/p>\n

15. Wet Age-Related Macular Degeneration (Wet AMD) Key Products<\/p>\n

16. Dormant and Discontinued Products<\/p>\n

17. Wet Age-Related Macular Degeneration (Wet AMD) Unmet Needs<\/p>\n

18. Wet Age-Related Macular Degeneration (Wet AMD) Future Perspectives<\/p>\n

19. Wet Age-Related Macular Degeneration (Wet AMD) Analyst Review<\/p>\n

20. Appendix<\/p>\n

21. Report Methodology<\/p>\n

21.1. Secondary Research<\/p>\n

21.2. Expert Panel Validation<\/p>\n

 <\/p>\n

To Know more about the disease, visit here<\/a>.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Ankit Nigam
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> NEVADA 89107
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Pipeline reports Wet Age-related Macular Degeneration Pipeline (Wet AMD Pipeline) analysis by DelveInsight offers a detailed description of Wet Age-related macular degeneration pipeline products, their expected launch, exhaustive competitive benchmarking, and key pharma companies working in the same field. … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,420,404],"tags":[],"class_list":["post-474060","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/474060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=474060"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/474060\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=474060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=474060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=474060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}